Compare Pfizer Inc (PFE) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.41 (market cap $72.20B). The key difference: Pfizer Inc is far larger — about 2.2× Vanguard Intermediate Term Corporate Bond ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vanguard Intermediate Term Corporate Bond ETF for 62 Days on average.
| PFE | VCIT | |
|---|---|---|
Market Cap | $158.56B | $72.20B |
Volume | 44,138,282 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $29.02 | $84.82 |
52-Week Low | $23.67 | $77.98 |
Typical Hold Time | 158 Days | 62 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $78.48, up 0.27% with a bearish technical signal from moving averages. The ETF offers a 4.8% yield and 5.1% yield-to-maturity with a 6-year duration, positioning it as a core fixed-income holding. Recent institutional buying includes Engineers Gate Manager's $1.27 million purchase and HB Wealth Management increasing holdings by 242.9%.
VCIT presents a compelling risk-return profile for income investors seeking corporate bond exposure with low costs. The 0.03% expense ratio provides cost efficiency versus competitors. Risks include interest rate sensitivity and corporate credit quality concerns. Technical indicators suggest near-term consolidation around $78 support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
